Protalix BioTherapeutics, Inc. PLX NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

53/100

2/7 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

共有 50 笔近期内部人交易记录记录，涉及 Protalix BioTherapeutics, Inc. (PLX), 包括 42 笔买入 和 4 笔卖出. 内部人买入总额为 $2.04M 内部人卖出总额为 $2.09M.

近期活跃的重要内部人包括 Bashan Dror, Bar-shalev Amos, Boudes Pol F. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.

内部人交易记录 — PLX

日期	姓名	职位	交易类型	股数	平均价格	总价值	持股数量
2025-12-19	Bashan Dror	President and CEO	知情买入	56,000	$1.81	$101.36K	188,516
2025-11-18	Bar-shalev Amos	Director	知情卖出	168	$1.87	$314.16	-
2025-09-03	Bar-shalev Amos	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Boudes Pol F	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Melincoff Gwen A	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Schwartz Aharon	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Naos Yaron	Sr. VP, Operations	限制性股票授予 (RSU)	50,000	$1.64	$82K	50,000
2025-09-03	Bashan Dror	President and CEO	限制性股票授予 (RSU)	340,000	$1.64	$557.6K	340,000
2025-09-03	Forster Eliot	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Ben Zvi Shmuel	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-09-03	Elze Christian	Director	限制性股票授予 (RSU)	7,500	-	-	7,500
2025-08-24	Mamlok Gilad	Sr. VP and CFO	未知	597,990	$1.45	$867.09K	-
2025-06-26	Elze Christian	Officer	未知	-	-	-	-
2025-06-10	Schwartz Aharon	Director	知情买入	129,000	$1.60	$205.88K	303,000
2024-09-23	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	99,010	-	-	669,010
2024-09-23	Naos Yaron	Sr. VP, Operations	限制性股票授予 (RSU)	100,000	$1.10	$110K	100,000
2024-09-23	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	90,909	-	-	660,909
2024-04-01	Bashan Dror	President and CEO	限制性股票授予 (RSU)	263,960	-	-	2,149,418
2023-10-19	Bashan Dror	President and CEO	知情买入	48,387	$1.40	$67.74K	116,387
2023-09-29	Bar-shalev Amos	Director	限制性股票授予 (RSU)	61,676	$1.66	$102.38K	61,676
2023-09-29	Boudes Pol F	Director	限制性股票授予 (RSU)	61,676	$1.66	$102.38K	61,676
2023-09-29	Melincoff Gwen A	Director	限制性股票授予 (RSU)	61,676	$1.66	$102.38K	61,676
2023-09-29	Schwartz Aharon	Director	限制性股票授予 (RSU)	61,676	$1.66	$102.38K	61,676
2023-09-29	Ben Zvi Shmuel	Director	限制性股票授予 (RSU)	61,676	$1.66	$102.38K	61,676
2023-09-14	Forster Eliot	Director	未知	-	-	-	-
2023-09-14	Forster Eliot	Director	限制性股票授予 (RSU)	85,715	$1.75	$150K	85,715
2023-08-15	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	201,903	-	-	570,000
2023-08-15	Naos Yaron	Sr. VP, Operations	限制性股票授予 (RSU)	187,344	-	-	200,817
2023-08-15	Bashan Dror	President and CEO	限制性股票授予 (RSU)	800,000	-	-	1,885,458
2023-08-15	Hayon Yael	VP, Research & Development	限制性股票授予 (RSU)	35,115	-	-	35,115
2023-01-03	Schwartz Aharon	Director	知情买入	110,000	$1.42	$155.82K	174,000
2022-09-07	Bronfeld Zeev	Director	限制性股票授予 (RSU)	100,000	-	-	100,000
2022-09-07	Bar-shalev Amos	Director	限制性股票授予 (RSU)	50,000	-	-	50,000
2022-09-07	Boudes Pol F	Director	限制性股票授予 (RSU)	50,000	-	-	50,000
2022-09-07	Melincoff Gwen A	Director	限制性股票授予 (RSU)	50,000	-	-	50,000
2022-09-07	Schwartz Aharon	Director	限制性股票授予 (RSU)	50,000	-	-	50,000
2022-09-07	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	350,000	-	-	350,000
2022-09-07	Naos Yaron	Sr. VP, Operations	限制性股票授予 (RSU)	340,000	-	-	340,000
2022-09-07	Bashan Dror	President and CEO	限制性股票授予 (RSU)	750,000	-	-	750,000
2022-09-07	Hayon Yael	VP, Research & Development	限制性股票授予 (RSU)	250,000	-	-	250,000
2022-09-07	Ben Zvi Shmuel	Director	限制性股票授予 (RSU)	10,000	-	-	10,000
2022-06-30	Ben Zvi Shmuel	Director	未知	-	-	-	-
2022-06-30	Ben Zvi Shmuel	Director	限制性股票授予 (RSU)	40,000	-	-	40,000
2022-04-11	Bashan Dror	President and CEO	知情买入	68,000	$1.50	$102K	68,000
2022-02-25	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	121,951	-	-	368,097
2022-02-25	Bashan Dror	President and CEO	限制性股票授予 (RSU)	637,531	-	-	1,085,458
2021-06-03	Dexcel Pharma Technologies Ltd.	10 Percent Owner	知情卖出	857,506	$2.25	$1.93M	3,637,314
2021-06-02	Dexcel Pharma Technologies Ltd.	10 Percent Owner	知情卖出	61,211	$2.56	$156.55K	4,494,820
2021-02-12	Dexcel Pharma Technologies Ltd.	10 Percent Owner	处置	-	-	-	4,556,031
2020-08-11	Rubin Eyal	Sr. VP and CFO	限制性股票授予 (RSU)	246,146	-	-	246,146